Citation Tools
PDFRheumatoid arthritis
Original research
Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies